Radiopharm Theranostics doses first patient in second cohort of RV-01 Phase 1/2a trial in B7-H3 solid tumors

• Radiopharm Theranostics dosed the first patient in cohort two of its Phase 1/2a trial of RV-01 in B7-H3 expressing solid tumors.
• The safety committee backed escalation to the next higher dose, supporting continued advancement through the study’s early testing stage.
• Initial clinical data have not been released; results are expected later in 2026.
• The trial is designed to assess safety and early signs of anti-tumor activity to guide dose selection for later-stage development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608260700PRIMZONEFULLFEED1001259345) on August 26, 2026, and is solely responsible for the information contained therein.